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Abstract
Aim: Basic fibroblast growth factor (bFGF) increases the migration and viability of bone marrow
mesenchymal stem cells (MSCs) in vitro. Retrograde coronary venous infusion can provide both
increased regional bFGF concentrations and homogeneous cell dissemination. We determined
whether retrograde delivery of bFGF enhances the potency of transplanted MSCs for cardiac
repair in a canine infarct model.
Methods and Results: Under hypoxic conditions, cellular migration was significantly increased in
MSCs co-cultured with bFGF compared to vascular endothelial growth factor or insulin-like
growth factor, and bFGF promoted MSCs differentiation into a cardiomyocyte phenotype. A canine infarct model was employed by coronary ligation. One week later, animals were subjected to
retrograde infusion of combination bFGF (200ng/mL) and MSCs (1×108 cells) (n=5), MSCs (1×108
cells, n=5), bFGF (200ng/mL, n=5), or placebo (phosphate-buffered saline, n=3). Four weeks after
infusion, only the bFGF+MSCs therapy exhibited significantly increased left ventricular ejection
fraction (LVEF) by echocardiography (p<0.01 vs pre-infusion), and the treatment effect (delta
LVEF) was greater in the bFGF+MSCs group compared to saline (7.43±1.51% versus
-10.07±2.94%; p<0.001). Morphologic analysis revealed an increased infarct wall thickness in the
bFGF+MSCs group compared to all others (p<0.05), accompanied by increased vascular density
and reduced apoptosis. Immunofluorescence demonstrated increased cell engraftment and enhanced vascular differentiation in the bFGF+MSCs group compared to MSCs alone (p<0.05).
Conclusions: Retrograde coronary venous bFGF infusion augments engraftment and differentiation capacity of transplanted MSCs, recovering cardiac function and preventing adverse remodeling. This novel combined treatment and delivery method is a promising strategy for cardiac
repair after ischemic injury.
Key words: Cell transplantation; Growth factor; Mesenchymal stem cells; Myocardial infarction; Retrograde.
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Introduction
Stem-cell based therapy has emerged as a potential therapeutic modality for regeneration and repair
of damaged myocardium after myocardial infarction
(MI) [1]. Bone marrow mesenchymal stem cells
(MSCs) are easily isolated and amplified, possessing
multilineage potential and apparent immuno-privilege, and are therefore a promising candidate
for cardiac regeneration therapy [2]. Numerous preclinical [3-5] and clinical studies [6, 7] have demonstrated the ability of MSCs to attenuate reverse remodeling and restore cardiac function following acute
MI. The underlying mechanisms include direct differentiation of implanted cells into new cardiomyocytes and vascular cells [8], augmented paracrine
signaling [9], and recruitment of endogenous stem
cells [3]. However, recent studies demonstrated limited in vivo differentiation capacity due to poor engraftment and survival of transplanted MSCs within
infarcted myocardium, resulting in modest therapeutic effects [10].
The efficiency of stem cell retention within injured myocardium is related to sufficient cellular extravasation and local growth factor gradients [11].
Basic fibroblast growth factor (bFGF) is a potent mitogen that can stimulate migration, proliferation, and
differentiation in various stem cell types [12]. In particular, bFGF increased the migratory activity of
MSCs via activation of the Akt/protein kinase B
pathway [13]. The bFGF-transfected MSCs exhibited
enhanced viability and anti-apoptotic properties under hypoxic conditions [14]. It is therefore plausible
that bFGF administration after MI may augment
MSCs migration and engraftment within injured tissue, thus improving the efficacy of MSCs transplantation.
Several approaches have been developed to
achieve extensive stem cell delivery into the damaged
heart [15, 16]. Although direct intramyocardial injection allows targeted cell delivery to ischemic regions,
this method may cause mechanical injury and subsequent acute inflammation, markedly reducing survival of engrafted cells [17]. Intracoronary administration is not ideal, as there is high risk of coronary
embolism[18], as well as low myocardial stem cell
retention in the face of antegrade blood flow [19]. In
contrast, percutaneous retrograde coronary venous
infusion represents an attractive alternative method
because it is minimally invasive, reproducible, and
has potential advantages of more uniform and higher
rate of delivery [15]. This technique achieved a 2-fold
increase in tissue binding of bFGF compared to intracoronary infusion [20]. Coronary vein route may
also provide more homogenous cell dissemination
across the myocardium [21, 22]. Heretofore, the effi-
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cacy of combination bFGF and MSCs via coronary
vein administration has not been investigated.
We hypothesized retrograde coronary venous
infusion may provide a high bFGF concentration, and
augment MSCs implantation by increasing the engraftment and survival of transplanted cells. To test
this hypothesis, we employed a canine infarct model,
and determined the effects of bFGF upon MSCs engraftment and differentiation via coronary vein infusion, and assessed their combined efficacy in improving cardiac repair via morphologic indices and
functional outcomes.

Methods
An expanded Methods section is available in the
Supplementary Materials.
This study conformed to the Interdisciplinary
Principles and Guidelines for the Use of Animals in Research, Testing, and Education by the New York
Academy of Sciences, Ad Hoc Animal Research
Committee. All protocols were approved by the Institutional Ethics Committee of Beijing Anzhen Hospital, Capital Medical University, China.
For this study, adult male mongrel dogs weighing 15-20 kg were subjected to MI via ligation of left
anterior descending (LAD) coronary artery and diagonal branches. After one week, all surviving animals underwent retrograde infusion of 10 mL of one
of the following: combination bFGF (200 ng/mL) and
MSCs (1×108 cells), MSCs alone (1×108 cells), bFGF
alone (200ng/mL), or placebo (phosphate-buffered
saline). Transthoracic echocardiography was performed at baseline, 1 week after MI (before infusion),
and 4 weeks after infusion (just prior to euthanasia).
After echocardiographic study, animals were euthanized, and the hearts were excised for histologic
analysis.

In vitro migration and differentiation assays
To assess the migration capacity of MSCs, a
24-well transwell dishes with 8-μm pore filters was
utilized. Cells were incubated with 50 ng/mL bFGF,
20 ng/mL vascular endothelial growth factor (VEGF),
2 ng/mL insulin-like growth factor (IGF-1), or medium alone. The number of migrated cells was
counted via fluorescent microscopy. All experiments
were tested under normoxic and hypoxic conditions.
To induce differentiation into a cardiomyocyte
phenotype, 2×104 MSCs were incubated with or
without 5 ng/mL bFGF. The differentiation capacity
was verified by morphology changes and immunostaining for troponin I (TnI).

Retrograde coronary venous infusion
Retrograde coronary venous infusion was performed as previously described [21]. From LAD corhttp://www.thno.org
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onary angiography, the position of over-the-wire
(OTW) balloon catheter was consistent with the occlusive site of the LAD (Figure 1). The balloon was
inflated, and the selected perfusion medium was
rapidly injected into the anterior interventricular vein
(AIV). The balloon remained inflated for 10 minutes
post injection to achieve maximum local delivery.

and cardiac myosin heavy chain (MHC). The survival
of engrafted cells was quantified in the infarct zone by
counting EGFP-positive (EGFP+) cells by fluorescent
microscopy. The differentiation capacity was evaluated based upon colocalization of EGFP with the endothelial cell marker FVIII, smooth muscle cell marker
α-SMA, and cardiomyocyte marker TnI.

Morphology and histology

Statistical analysis

After echocardiographic study, cardiectomy was
performed. Thereafter, the left ventricular (LV) myocardium was transversely sliced along the apical-basal
axis. For morphologic analysis, infarct wall thickness
was measured at the level of the papillary muscle, and
calculated as a percentage of septal wall thickness.
Hematoxylin and eosin, and Masson trichrome staining were performed as previously described. Fibrotic
area was calculated by the proportion of collagen-stained areas to total tissue area. Blood vessel
density was determined at the border zone of the
myocardium by immunostaining with factor
VIII-related antigen (FVIII) and α-smooth muscle actin (α-SMA). Apoptosis was detected with an in situ
cell death detection kit per manufacturer protocol.

All values are presented as mean±SEM unless
otherwise indicated. Statistical assessments were
performed using SPSS 19.0 (SPSS Science, Chicago,
IL). GraphPad Prism (version 5.0; GraphPad Software
Inc, La Jolla, CA) was used to plot graphs. Data were
first tested for normality (Kolmogorov-Smirnov test)
and equality of variance (Levene’s test). After confirmation of both normality and variance equality,
comparisons between two groups were determined
by unpaired Student t test, and comparisons among
multiple groups were made by 1-way or 2-way analysis of variance (ANOVA), followed by Tukey post
hoc test when appropriate. The Welch correction was
applied when unequal variances were identified. Intragroup comparisons at different time points were
performed by paired Student t test. Changes in echocardiography parameters over time among different
groups were evaluated using 2-way repeated
measures ANOVA with Bonferroni posttests when
appropriate. A value of 2-tailed p<0.05 was considered statistically significant.

Immunofluorescence
The engraftment and differentiation of MSCs
were evaluated in the MSCs (n=3) and bFGF+MSCs
(n=3) groups. MSCs were labeled with enhanced
green fluorescence protein (EGFP) and infused into
the AIV. After four weeks, frozen sections (7 μm) were
incubated with antibodies against FVIII, α-SMA, TnI,

Figure 1. Retrograde coronary venous infusion. (A) Angiogram of the left coronary artery demonstrating occlusion of the left anterior descending (LAD) coronary artery
(middle) (white arrow). (B) Retrograde venography of coronary sinus. (C) A 0.014-inch exchange-length extra support guide wire was advanced to the distal portion of anterior
interventricular vein (AIV). (D) Angiogram of the left coronary artery demonstrating parallel guide wire travel to the LAD (white arrowheads). (E) An over-the-wire (OTW)
balloon catheter (2.5×9 mm or 2.0×9 mm) was advanced and positioned in the mid-AIV. (F) Balloon inflation and simultaneous visualization of the left coronary artery showed
that balloon position was consistent with the occlusive site of the LAD (white arrow). The delivery site was within the targeted infarct zone.
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Figure 2. Basic fibroblast growth factor (bFGF) promotes mesenchymal stem cells (MSCs) migration and differentiation into a cardiomyocyte phenotype
in vitro. (A) MSCs were cultured under normoxic and hypoxic conditions with 50 ng/mL bFGF, 20 ng/mL vascular endothelial growth factor (VEGF), 2 ng/mL insulin-like growth
factor (IGF-1), or control medium. Under hypoxic conditions, the number of migrated cells increased when incubated with VEGF, IGF-1, and bFGF. (B) Myotube-like structures
were observed in differentiated MSCs (dMSCs). (C) Cotreatment with bFGF induced MSCs differentiation into a cardiomyocyte phenotype, as indicated by increased cardiac
troponin I positive (TnI+) cells. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). Scale bars: 200μm (A); 100μm (B and C). Histograms represent mean±SEM. A:
*p<0.05 vs normoxia; †p<0.05 vs control. All with 2-way ANOVA. C: *p<0.05 vs control, unpaired Student t test.

Results
Study animals
In total, 32 animals were subjected to MI. 7 animals had refractory ventricular fibrillation during
surgery, and could not be resuscitated. 2 animals died
at days 2 and 5 after infarction, likely due to congestive heart failure. Before infusion, 4 animals were excluded (3 with coronary vein anomalies precluding
successful catheterization, and 1 with inadequate
echocardiography imaging). The remaining 19 animals were randomly assigned to treatment with saline
(n=4), bFGF (n=5), MSCs (n=5), and bFGF+MSCs
(n=5). There were no instances of death, cardiac
tamponade, or sustained arrhythmia during infusion.
One animal in the saline group died 4 days post infusion. Finally, 18 animals (saline [n=3], bFGF [n=5],
MSCs [n=5], and bFGF+MSCs [n=5]) were included in
the analysis.

bFGF promotes MSCs migration and differentiation into a cardiomyocyte phenotype in
vitro
The number of migrated cells was significantly
greater when incubated under hypoxic versus
normoxic conditions in control (p=0.006), IGF-1

(p=0.002), and bFGF (p<0.001) groups (Figure 2A).
During hypoxia, MSCs exhibited increased migratory
ability when cultured with VEGF, IGF-1, and bFGF
(all p<0.001 vs control).
To confirm whether bFGF stimulates MSCs differentiation into a cardiomyocyte phenotype in vitro,
we observed the morphology and cardiac-specific TnI
expression of MSCs with or without bFGF. Differentiated MSCs showed myotube-like structure after 2
weeks (Figure 2B). The bFGF-treated MSCs expressed
greater TnI expression. Quantitative analysis revealed
that the number of the TnI+ cells was significantly
higher in the presence of bFGF versus control medium (32.8±2.3% vs 27.0±1.2%; p=0.015; Figure 2C).

Retrograde infusion of combining bFGF and
MSCs improves cardiac function after MI
We tested whether bFGF might enhance the potential of transplanted MSCs for cardiac repair by
serial echocardiographic analysis at baseline (before
MI), 1 week after MI (before infusion), and 4 weeks
after infusion (Table 1, Figure 3). The LV structure and
function parameters at baseline and before infusion
were comparable among the 4 groups (p>0.05) (Table
1, Figure 3A, 3C, and 3E). LV ejection fraction (LVEF)
was improved in the bFGF+MSCs group by 11%
(p<0.01), but remained unchanged in the bFGF group
http://www.thno.org
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(p=0.480) and MSCs group (p=0.124), and decreased in
the saline group (p<0.01) after 4 weeks (Figure 3A).
The treatment effect (delta LVEF) was significantly
greater in both the bFGF+MSCs group (7.43±1.51%
versus -10.07±2.94%; p<0.001) and MSCs group
(4.79±2.47% versus -10.07±2.94%; p<0.01) compared to
saline, to greater degree in the combination group
(Table 1, Figure 3B).
The left ventricular end-diastolic volume
(LVEDV) increased in all groups (all p<0.05; Figure
3C), with modest attenuation in the intervention
groups compared with saline group (ANOVA
p=0.053; Table 1, Figure 3D). Furthermore, the left

999
ventricular end-systolic volume (LVESV) remained
stable in the intervention groups, but increased in the
saline-treated group (p<0.001; Figure 3E). The absolute changes suggested attenuation of LVESV in the
intervention groups (all p<0.05 vs saline), to greatest
degree in the combination group (Table 1, Figure 3F).
Left ventricular end-diastolic diameter (LVEDD)
and left ventricular end-systolic diameter (LVESD)
demonstrated progressive chamber expansion in the
saline group, a phenomenon not observed in the other
treatment groups. All four groups exhibited decreased fractional shortening (FS) prior to treatment,
without improvement after 4 weeks (Table 1).

Figure 3. Retrograde infusion of combining basic fibroblast growth factor (bFGF) and mesenchymal stem cells (MSCs) restores cardiac function and
prevents left ventricular (LV) remodeling. Echocardiographic analysis of (A) LV ejection fraction (LVEF), (C) LV end-diastolic volume (LVEDV), and (E) LV end-systolic
volume (LVESV) before infusion and 4 weeks after treatment. The treatment effect (final minus pre-infusion parameters) was also evaluated (B, D, and F). (A) LVEF was improved
in the bFGF+MSCs group, but remained unchanged in the bFGF group and MSCs group, and decreased in the saline group. The final LVEF and (B) the treatment effect were
increased in the MSCs and bFGF+MSCs groups, to greater degree in the latter. (C) All groups exhibited increased LVEDV after infusion, with (D) mild attenuation in the
intervention groups (not statistically significant). (E) LVESV remained stable in the intervention groups, but increased in the saline-treated group. At 4 weeks, the combined
therapy presented lower LVESV in comparison to saline and bFGF alone groups. (F) The delta changes of LVESV demonstrated significant attenuation in the bFGF alone, MSCs
alone, and bFGF+MSCs groups, to greatest degree in the combination group. Histograms (A, C, and E) show pre-infusion vs 4 weeks post-infusion values. Histograms represent
mean±SEM. A, C, and E: *p<0.05 vs pre-infusion, paired t test; †p<0.05 vs saline, ‡p<0.05 vs bFGF, between-group repeated measures ANOVA. B, D, and F: *p<0.05 vs saline,
1-way ANOVA with Tukey post hoc test.

Table 1. Echocardiographic analysis.

http://www.thno.org
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Parameters
LVEDD (mm)
Baseline
Pre-infusion
Final
Treatment effect
LVESD (mm)
Baseline
Pre-infusion
Final
Treatment effect
FS (%)
Baseline
Pre-infusion
Final
Treatment effect
LVEDV (mL)
Baseline
Pre-infusion
Final
Treatment effect
LVESV (mL)
Baseline
Pre-infusion
Final
Treatment effect
LVEF (%)
Baseline
Pre-infusion
Final
Treatment effect
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Saline (n=3)

bFGF (n=5)

MSCs (n=5)

bFGF+MSCs (n=5)

p value (ANOVA)

34.24±1.73
36.92±0.46
40.07±0.57
3.14±0.67

35.62±0.65
36.69±0.93
37.70±1.18
1.01±0.89

34.38±1.38
35.43±1.70
36.28±1.97
0.85±0.93

32.90±2.28
34.20±2.44
34.86±1.76
0.66±1.00

0.659
0.696
0.275
0.351

20.00±1.19
22.33±0.73
26.50±0.36
4.17±0.91

20.99±1.68
24.16±3.24
26.36±2.53
2.20±3.24

21.53±0.89
23.20±1.31
24.08±1.63
0.88±0.74

19.67±1.29
21.49±2.18
21.73±1.90
0.25±0.84

0.662
0.815
0.273
0.124

41.64±0.67
39.54±1.24
33.86±0.38
-5.69±1.61

41.17±4.02
34.31±8.04
30.02±6.86
-4.29±9.40

37.25±1.93
34.45±2.26
33.52±3.06
-0.92±1.38

40.09±1.42
37.61±2.54
37.84±3.57
0.23±2.34

0.467
0.411
0.587
0.265

50.21±1.70
58.07±1.59
71.04±1.53
12.98±1.11

52.48±3.21
61.11±3.28
67.61±2.15
6.50±1.40

46.89±3.06
50.48±3.85
58.92±5.34
8.44±1.58

44.09±7.14
49.67±7.47
56.46±6.56
6.79±1.28

0.622
0.291
0.273
0.053

11.93±1.61
18.12±0.88
29.32±1.63
11.20±1.57

13.18±1.91
19.91±3.23
22.76±4.10
2.84±0.90

14.63±0.59
17.99±0.73
18.04±1.37
0.05±1.26

12.40±1.87
15.92±1.80
14.34±1.78
-1.57±0.23

0.607
0.729
0.003
0.005

76.40±2.44
68.80±1.15
58.73±2.07
-10.07±2.94

75.16±2.19
67.60±4.12
66.59±5.07
-1.01±1.17

68.40±1.84
63.84±1.93
68.63±2.92
4.79±2.47

71.59±1.78
67.17±1.43
74.61±1.14
7.43±1.51

0.066
0.420
0.016
<0.001

Values are mean±SEM. Treatment effect indicates final minus pre-infusion parameters.
LVEDD indicates left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; FS, fractional shortening; LVEDV, left ventricular end-diastolic
volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction; bFGF, basic fibroblast growth factor; MSCs, mesenchymal stem cells.

Combined therapy with bFGF and MSCs increases infarct thickness and alleviates myocardial fibrosis
Gross morphologic analysis revealed midmural
scars in the LV anterior and anteroseptal walls (Figure
4A). The average infarct wall thickness was increased
in the bFGF+MSCs group (8.2±0.2mm) compared
with saline (4.8±0.1mm), bFGF (6.2±0.2mm), and
MSCs (6.6±0.1mm) groups (all p<0.05; Figure 4A).
Additionally, the percentage of infarct wall to septal
wall thickness was greatest in the bFGF+MSCs group
(Figure 4A).
Masson’s trichrome staining showed decreased
collagen content in the infarct area in the MSCs alone
group
(51.5±1.9%)
and
bFGF+MSCs
group
(47.3±1.6%), compared to the bFGF group (59.8±2.9%)
and saline group (59.7±3.9%) (all p<0.05; Figure 4B), to
greater degree in the combination group. Reduced
border zone collagen content was observed in the
MSCs alone group (38.1±2.3%; p<0.05) and
bFGF+MSCs group (36.6±1.8%; p<0.05) compared to
saline (47.7±1.7%) (Figure 4B). Interestingly, more
myocardium islets were detected within the infarct
scars of the combination-treated animals.

Combined therapy with bFGF and MSCs
stimulates new blood vessel formation and
reduces apoptosis
Capillary and arteriole density was determined
(respectively by FVIII and α-SMA staining) in the infarct border zones. The number of FVIII+ cells was
markedly greater in the bFGF+MSCs group
compared
to
the
saline
(97.1±8.3/mm2)
(40.0±5.3/mm2; p<0.001), bFGF (60.0±5.2/mm2;
p<0.01), and MSCs (54.3±5.4/mm2; p<0.001) groups
(Figure 5A). The arteriolar density was significantly
greater in the bFGF+MSCs group (35.7±3.2/mm2)
compared to the saline (15.0±2.4/mm2; p<0.05) and
MSCs (23.6±2.4/mm2; p<0.05) groups (Figure 5B).
Apoptosis was assessed by the proportion of
TUNEL+ cells in the infarct border zone, which was
significantly decreased in the animals treated with
bFGF+MSCs (8.2±0.9%) compared to saline
(14.6±0.9%; p<0.01) (Figure 5C), but similar to bFGF
alone (12.5±1.7%) and MSCs alone (12.3±0.5%).

bFGF enhances engraftment and differentiation of transplanted MSCs
To address whether bFGF improved MSCs engraftment and survival, the transplanted cells were
http://www.thno.org
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labeled with EGFP and observed in the myocardium 4
weeks after delivery. The EGFP+ cells localized primarily in the infarct and border zones (Figure 6A-6D).
The number of EGFP+ cells was 1-fold higher in the
bFGF+MSCs group (83.9±9.6/mm2) compared to the
MSCs alone group (42.3±7.4/mm2; p<0.05) (Figure
6E).
Surviving MSCs mainly differentiated into vascular structures, indicated by positive staining with
FVIII (Figure 6A) and α-SMA (Figure 6B). Compared
to the MSCs group, the bFGF+MSCs group exhibited
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more FVIII+ (30.2±3.1/mm2 vs 8.9±1.8/mm2; p<0.001)
and α-SMA+ (9.9±0.7/mm2 vs 3.9±0.4/mm2; p<0.05)
cells (Figure 6F). Moreover, the coexpression of TnI
and MHC in EGFP+ cells indicated some MSCs had
differentiated into a cardiomyocyte phenotype (Figure 6C and 6D), although no significant difference
was found between the two groups (Figure 6F). Collectively, bFGF appears to enhance the differentiation
capability of MSCs under both hypoxic conditions
(Figure 2C) and infarction circumstances (Figure 6).

Figure 4. Combined administration of basic fibroblast growth factor (bFGF) and mesenchymal stem cells (MSCs) increases infarct wall thickness and
reduces myocardial fibrosis. (A) Post-mortem morphometry revealed midmural scars in the left ventricular wall. Coronary venous infusion of bFGFs+MSCs increased infarct
wall thickness compared to other groups. The percentage of infarct wall thickness to septal wall thickness was greatest in the bFGF+MSCs group. (B) Masson’s trichrome staining
showed decreased collagen content in the MSCs and bFGF+MSCs groups both in the infarct and border zones. Scale bar: 100μm. Histograms represent mean±SEM. A: *p<0.05
vs saline; †p<0.05 vs bFGF and MSCs groups. B: *p<0.05 vs saline; †p<0.05 vs bFGF.

http://www.thno.org
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Figure 5. Combined administration of basic fibroblast growth factor (bFGF) and mesenchymal stem cells (MSCs) induces neovascularization and inhibits
apoptosis. Representative micrographs demonstrated formation of (A) new capillaries and (B) arterioles in the infarct border region after treatment. Quantitative analysis
indicated markedly greater (A) capillary density (evidenced by factor VIII-related antigen [FVIII] staining) and (B) arteriole density (evidenced by α-smooth muscle actin [α-SMA]
staining) in the bFGF+MSCs group. (C) Representative images of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells in the border region of the
infarct myocardium. Cell nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI). The proportion of TUNEL+ cells was significantly decreased in the bFGF+MSCs
group. Scale bars: 50μm (A); 100μm (B); 20μm (C). Histograms represent mean±SEM. *p<0.05 vs saline; †p<0.05 vs bFGF; ‡p<0.05 vs MSCs. All with 1-way ANOVA by Tukey
post hoc test.

Discussion
In the present study, we demonstrate the coronary vein is a feasible and safe route for delivery of
bFGF and MSCs. bFGF augments the engraftment and
differentiation of transplanted MSCs in vivo. Retrograde infusion of MSCs with concomitant bFGF results in enhanced cardiac function recovery and prevention of LV remodeling post-MI. Increased neovascularization and reduced apoptosis are also observed. Taken together, these data indicate that concomitant bFGF and MSCs via coronary vein infusion
confers improved therapeutic efficacy in a canine MI
model, thereby representing a promising future
strategy for cardiac repair after ischemic insult.

MSCs as a Candidate for Cardiac Regeneration
Therapy
In the past decade, numerous studies have been
seeking an ideal stem-cell type suitable for cardiac
repair. Indeed, MSCs are a desirable agent for myo-

cardial repair because of preparatory ease, advantageous immunomodulatory properties, and favorable
biological effects [2]. On the basis of encouraging
pre-clinical studies [3-5], proof-of-concept clinical
trials have been initiated for both acute MI [7] and
ischemic cardiomyopathy [6] and demonstrated that
MSCs therapy improved cardiac performance, inhibited LV remodeling, and reduced scar size, with a
remarkable safety profile. Recently, studies have focused upon the candidacy of resident cardiac stem
cells (CSCs) for cardiac repair, due to their cardiac
source and potent cardiomyogenic potential [23, 24].
In large animal models, CSCs injection improved LV
function and reduced scar size with evidence of cardiomyocyte and vascular regeneration [25]. However,
recent clinical trials (SCIPIO [26] and CADUCEUS
[27]) revealed inconsistent results in terms of LVEF,
symptoms, or quality of life after intracoronary CSCs
administration in patients with ischemic cardiomyopathy. The CSCs ready for transplantation must be
autologous, and require several weeks of in vitro exhttp://www.thno.org
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pansion, factors limiting their use in the acute MI setting [23]. It is clinically impractical to perform endomyocardial biopsy immediately after infarction.
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Therefore, generic allogenic MSCs remain the most
accessible cell product for cardiac regeneration therapy at the current time.

Figure 6. Retrograde infusion of basic fibroblast growth factor (bFGF) enhances mesenchymal stem cells (MSCs) engraftment and differentiation. Representative immunofluorescence images demonstrated coexpression of (A) factor VIII-related antigen (FVIII), (B) α-smooth muscle actin (α-SMA), (C) cardiac troponin I (TnI),
and (D) cardiac myosin heavy chain (MHC) in enhanced green fluorescence protein (EGFP) positive cells in the infarct region. Nuclei were stained with
4,6-diamidino-2-phenylindole (DAPI). (E) The number of EGFP+ cells was 1-fold higher in the bFGF+MSCs group than in the MSCs group. (F) The number of labeled cells
costained with FVIII and α-SMA was significantly greater in the animals treated with bFGF+MSCs (n=3) compared with MSCs (n=3), indicating enhanced neovascularization by
combined therapy. The number of EGFP+ cells coexpressing TnI was not statistically different between the two groups. Scale bars: 100μm (A, C and D); 200μm (B). Histograms
represent mean±SEM. *p<0.05 vs MSCs, unpaired Student t test.

http://www.thno.org
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Combined efficacy of bFGF and MSCs
Despite the beneficial effects of MSCs, the clinical application is impeded by poor engraftment and
survival of transplanted cells in the host myocardium.
In animal studies, the average retention rate was less
than 10% in the acute phase of MI [19, 28], and only
5% of implanted MSCs survived for 14 days in the
infarcted myocardium regardless of the delivery route
[16]. Targeted homing of MSCs towards injured tissue
is modulated by several growth factors [11]. Our vitro
studies demonstrated increased MSCs migratory activity during coculture with bFGF, in consistent fashion with previous studies [13]. Therefore, it is plausible the combination of MSCs with bFGF might facilitate increased cellular engraftment and therapeutic
potency. Takehara et al. demonstrated controlled
bFGF
delivery
promoted
human
cardiosphere-derived cell engraftment with improved ventricular function [29]. In parallel, we now demonstrate
bFGF cotreatment augments MSCs retention within
the host myocardium with increased LVEF.
LV remodeling is characterized by wall thinning
and chamber dilatation and leads to worsen cardiac
function. Previous studies have shown administration
of stem cells can increase infarct wall thickness and
improved ventricular remodeling, probably by alleviating myocardial fibrosis and reducing apoptosis.
Ye et al. [30] used a swine MI model and presented
that intramyocardial injection of thymosin β4 and
MSCs significantly increased the percentage of infarct
wall thickness to septal wall thickness compared to
control group (50% vs. 25%, p<0.05). Houtgraaf et al.
[31] used a sheep MI model and demonstrated intracoronary infusion of mesenchymal precursor cells
significantly enhanced the average infarct wall thickness compared to control group (8.0±0.3 mm vs.
6.4±0.2mm, p<0.001). In consistent with these studies,
our results showed the infarct wall thickness was increased in the MSCs group (6.6±0.1mm) compared
with saline (4.8±0.1mm, p<0.05), and bFGF+MSCs
group exhibited more obvious wall thickness improvement (8.2±0.2mm, p<0.05 vs all the other
groups). The combination group also exhibited alleviated myocardial fibrosis and apoptosis. These results can explain the significant improvement of infarct wall thickness in the combined treatment group.
To further clarify the underlying mechanism of
the beneficial effects of combined treatment, the fate
of injected MSCs was monitored by dual labeling with
EGFP and cardiac-specific markers. We found the
engrafted MSCs primarily differentiated into endothelial cells and smooth muscle cells, as indicated by
coexpression of EGFP with FVIII and α-SMA, suggesting vascular regeneration. This phenomenon was
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more evident in the combination bFGF+MSCs group.
Differentiation of MSCs into cardiomyocytes was also
observed, but was not enhanced by bFGF. In fact, the
differentiation capacity of transplanted MSCs in the
ischemic heart is influenced by many factors and the
study results are conflicting. In a swine model of
chronic ischemic cardiomyopathy, Quevedo et al. [8]
reported the capacity of allogeneic MSCs to engraft
and differentiate into cardiomyocytes, smooth muscle
cells and endothelial cells. In contrast, in a canine
chronic ischemic model, Silva et al. [4] showed that
MSCs can differentiate into cells with a vascular
phenotype, but few cardiomyocytes differentiated
from MSCs were detected. Actually, the average retention rate of MSCs was low in the acute phase of MI,
and the morphology and mobility of transplanted
MSCs were also impaired in the infarcted myocardial
environment [32]. It thus appears that the overall
differentiation ratio of MSCs into cardiomyocytes was
relatively low. Therefore, in our study, although retrograde infusion of bFGF significantly enhanced
MSCs engraftment in the myocardium, the number of
cardiomyocytes differentiated from MSCs was modestly increased by bFGF, and the engrafted MSCs
mainly differentiated into vascular cell lineage, which
is consistent with previous studies.
The harsh ischemic microenvironment, characterized by oxidative stress, inflammation, and limited
blood supply, hinders the survival of transplanted
MSCs [33]. The bFGF involved in the MSCs secretome
stimulates angiogenesis, and improves the ischemic
surroundings [34]. Although bFGF alone promoted
new arteriolar formation, LV functional improvements could not be reached without the MSCs. Our
study demonstrated concomitant bFGF infusion with
MSCs ameliorated myocardial fibrosis, increased capillary/arteriolar density, and reduced apoptosis,
effects that may stem from bFGF-induced angiogenesis and MSCs differentiation. Together, these observations support the notion that the interaction between bFGF and MSCs synergistically optimized
measured outcomes.

Mode of delivery
Heretofore, the optimal delivery technique of
candidate cells to the heart remains undetermined. An
ideal system must attain a desired cell population,
and facilitate targeted and homogeneous cell dissemination within the myocardium with low risk of
complications. Direct surgical injection provides a
great cell population per unit area, but is limited by
non-uniform spatial distribution [17]. Intracoronary
administration is easy to perform, but immediate cell
retention is low due to rapid wash out [19]. Additionally, this approach carries a high risk of microhttp://www.thno.org
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vascular occlusion when large cells, such as MSCs, are
infused [18]. Currently available transendocardial
injection enables cell delivery into targeted myocardium [35]. However, this technique may create cell
clumps without homogeneous distribution, and myocardial perforation and arrhythmias must be monitored [2, 18].
In contrast, the retrograde route is an attractive
mode of delivery because it employs the non-diseased
coronary veins, which parallel the arterial system, for
selective delivery to ischemic myocardium [36]. Increased tissue penetration using this method is probably due to improved access to low-pressure capillary
beds, and less washout of cells in the presence of reduced anterograde blood flow [36]. Yokoyama and
colleagues [37] demonstrated >90% of labeled mononuclear cells remained in the infarct region post
coronary vein infusion. Suzuki and colleagues [22]
reported retrograde delivery of skeletal muscle precursor cells provided wide dissemination throughout
the left ventricular free wall, with minimal myocardial
damage. Our study demonstrated the balloon position
was consistent with the occlusive LAD site (Figure 1).
The delivery site was within the targeted infarct zone.
As a result, the transplanted MSCs engrafted primarily within the desired region downstream of the occluded LAD.
To maximize the beneficial effects of bFGF upon
MSCs, we utilized for the first time a retrograde approach, for the concomitant infusion of bFGF and
MSCs. Previous study showed coronary vein infusion
of MSCs prevents cardiac dysfunction in a chronic pig
MI model, but with limited cell retention and differentiation [38]. In our study, we employed a proximal
balloon occlusion, achieving a bFGF reservoir, which
exerted sustained effect upon MSCs. Our results revealed combination therapy with bFGF and MSCs
augmented cell engraftment and differentiation, with
enhanced cardiac structural and functional performance.

Limitations
The canine model employed in our study might
limit interpretation of cardiac functional data, because
dogs develop numerous collateral circulations in ischemic conditions. We attempted to decrease this
physiologic effect as much as possible by diagonal
branches ligation whenever appropriate. Although
each group’s sample size is small, statistical significances were observed between treatment groups in
both echocardiographic parameters and histologic
findings. More advanced modalities such as 3D
echocardiography and cardiac magnetic resonance
imaging should be considered for more accurate assessment of cardiac morphology and function, espe-
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cially when sample size is small. This study used an
OTW balloon catheter to provide proximal occlusion
for cell infiltration, but this technique would not
overcome cell washout due to venovenous communications. A double-balloon catheter design is promising [19]. Free exogenous bFGF might have limited
efficacy due to short half-life in the body. In consideration of this question, we used retrograde coronary
venous approach to achieve high local concentration
and more uniform delivery. Further studies using
bFGF modification technique (eg. nanoparticles) to
increase the half-life of bFGF are needed. The coupling of exogenous MSCs with native cardiomyocytes
can better identify the engraftment and differentiation
of transplanted MSCs within host myocardium, and
have been investigated by several previous studies [3,
39], although it is not the focus of our study. Importantly, the signal pathway involved in the interplay between bFGF and MSCs for cardiac repair remains unclear, and warrants rigorous investigation.

Supplementary Materials
Supplementary Methods.
http://www.thno.org/v05p0995s1.pdf

Conclusions
The present study demonstrated retrograde
coronary venous bFGF infusion enhances the engraftment and differentiation capacity of transplanted
MSCs in response to MI injury. Co-administration of
bFGF and MSCs significantly improves cardiac function and ameliorates adverse remodeling, which is
accompanied by increased neovascularization and
reduced apoptosis. Taken together, our findings suggest a novel combined therapy via retrograde infusion
may represent a promising strategy for cardiac repair
after ischemic injury.
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